| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
| Products Intro: |
Product Name:catuMaxoMab
CAS:509077-98-9
Purity:99% HPLC Package:50Mg,100Mg,500Mg,1g,5g,10g,50g,100g,500g,1kg Remarks:XYA1196
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Products Intro: |
Product Name:catuMaxoMab
CAS:509077-98-9
Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604862 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Catumaxomab (DHD17406)
CAS:509077-98-9
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | catumaxomab Basic information |
| | catumaxomab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | catumaxomab Usage And Synthesis |
| Description | Catumaxomab is an anti-Ep-CAM monoclonal antibody, it has been designed to induce more efficient killing of epithelial tumor cells. More specifically, catumaxomab is a bispecific trifunctional antibody (trAb). In addition to its EpCAM recognition arm, it possesses an anti-CD3 arm that targets the T-cell antigen CD3; binding to the CD3 receptor activates T cells to release cytotoxic cytokines and to promote T cell-mediated lysis. In essence, catumaxomab consists of one half of an anti-Ep-CAM antibody and one half of an anti-CD3 antibody. The trifunctionality comes into play with an intact Fc region that selectively binds to FCg receptor-positive accessory cells, such as macrophages, dendritic cells, and natural killer (NK) cells that promote phagocytosis and antibody-dependent cell cytotoxicity. As a trAb that brings the requisite immune effector cells in close proximity to the tumor cells, catumaxomab destroys tumor cells possessing the surface antigen Ep-CAM via simultaneous activation and complex crosstalk of T cells and accessory immune cells. While it has gained approval for the intraperitoneal (i.p.) treatment of malignant ascites caused by Ep-CAM-positive metastatic epithelial-derived tumors, it is also being evaluated for the treatment of ovarian and gastric cancers. | | Originator | TRION
Pharma (Germany) | | Brand name | Removab |
| | catumaxomab Preparation Products And Raw materials |
|